Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Clinigen set to snap up Quantum Pharma in £150mln cash-and-shares deal

Clinigen said Quantum is a “sound cultural fit” and the acquisition should provide “immediate financial benefits”
scientist looking through a microscope
The acquisition makes sense given both firms' focus on developing niche medicines

Clinigen Group PLC (LON:CLIN) is closing in on the acquisition of fellow AIM-listed specialty pharma Quantum Pharma PLC (LON:QP.) after the two agreed a £150mln cash-plus-shares deal.

The offer, which has been recommended by Quantum to its shareholders, will see Clinigen pay 37p in cash and 0.0405 new Clinigen shares for each Quantum share.

WATCH: Andrew Hoare on Clinigen's well-timed swoop on Quantum Pharma

Based on Clinigen’s closing price of £11.11 yesterday, that values each Quantum share at 82p and the total offer at £150.3mln.

‘Sound cultural fit’

Clinigen, which began discussions over a possible takeover last month, said Quantum was a “sound cultural fit” and that the acquisition would add “immediate financial benefits”.

The company – which is worth more than £1bn – added that Quantum provides it with a European presence while its international footprint can give Quantum a global reach for its generic licensed products.

WATCH: Quantum Pharma acquisition 'the logical next step' in growth story for Clinigen

The acquisition is also expected to “enhance Clinigen’s position as the global leader in ethical access to unlicensed medicines”.

Merger set to benefit both firms

"The earnings enhancing acquisition of Quantum is an excellent operational and geographical, as well as cultural, fit with Clinigen,” said Clinigen chief executive Shaun Chilton.

“Quantum's UL2L (unlicensed to licensed) capabilities will provide a bridge between our unlicensed and commercial businesses, mirroring our business in the AAA region. Quantum's expertise in this area will enable us to boost our global UL2L ambitions.

READ: Clinigen confirms it is in talks to take over Quantum Pharma

"With the addition of Quantum, we will be in a stronger position to drive our global expansion in the unlicensed and commercial medicine markets."

Quantum boss Chris Rigg added: "The Quantum board is excited by the prospects of the enlarged group and Quantum's role in it."

WATCH: Clinigen achieves a pharma first with EC Cardioxane approval

The acquisition is being funded from existing banking facilities.

Clinigen said it has received irrevocable undertakings – investors who have agreed to sell their shares – from Quantum shareholders representing 19% of the share capital.

View full CLIN profile View Profile

Clinigen Group PLC Timeline

Related Articles

picture of human skeleton
July 21 2017
Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln
blood cells
October 04 2017
The two parts of the business - the commercial arm and research function - appear to be firing on all cylinders
1506367758_shutterstock_118491940.jpg
September 26 2017
The firm received an order for its clinical research use only (RUO) kits from a large, multinational pharma company

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use